Stefan W Krause

List of Publications by Year
in descending order

91 papers	8,386 citations	57719 44 h-index	48277 88 g-index
93 all docs	93 docs citations	93 times ranked	11250 citing authors

#	Article	IF	Citations
1	CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome. Blood, 2022, 139, 87-103.	0.6	82
2	Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: results from a large multicenter study. Blood Advances, 2022, 6, 1394-1405.	2.5	17
3	Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations. Journal of Hematology and Oncology, 2022, 15, 60.	6.9	17
4	Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial. Leukemia, 2022, 36, 1870-1878.	3.3	47
5	Reproducible measurable residual disease detection by multiparametric flow cytometry in acute myeloid leukemia. Leukemia, 2022, 36, 2208-2217.	3.3	8
6	The effect of erythrocyte lysing reagents on enumeration of leukocyte subpopulations compared with a noâ€lyseâ€noâ€wash protocol. International Journal of Laboratory Hematology, 2021, 43, 939-947.	0.7	2
7	Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia: long-term follow-up of the randomized controlled SORAML trial. Leukemia, 2021, 35, 2517-2525.	3.3	40
8	Loss-of-Function Mutations of BCOR Are an Independent Marker of Adverse Outcomes in Intensively Treated Patients with Acute Myeloid Leukemia. Cancers, 2021, 13, 2095.	1.7	7
9	Impact of PTPN11 mutations on clinical outcome analyzed in 1529 patients with acute myeloid leukemia. Blood Advances, 2021, 5, 3279-3289.	2.5	21
10	Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia. Blood Cancer Journal, 2021, 11, 164.	2.8	29
11	On Its Way to Primetime: Artificial Intelligence in Flow Cytometry Diagnostics. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2020, 97, 990-993.	1.1	4
12	EZH2 mutations and impact on clinical outcome: an analysis in 1,604 patients with newly diagnosed acute myeloid leukemia. Haematologica, 2020, 105, e228-e231.	1.7	29
13	High-risk additional chromosomal abnormalities at low blast counts herald death by CML. Leukemia, 2020, 34, 2074-2086.	3.3	50
14	Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia?. Blood, 2020, 136, 823-830.	0.6	85
15	Blood counts in adult and elderly individuals: defining the norms over eight decades of life. British Journal of Haematology, 2020, 189, 777-789.	1.2	22
16	Reticulated platelets â€“ clinical application and future perspectives. Journal of Laboratory Medicine, 2020, 44, 241-253.	1.1	4
17	Aspergillusspecific nestedPCRfrom the site of infection is superior to testing concurrent blood samples in immunocompromised patients with suspected invasive aspergillosis. Mycoses, 2019, 62, 1035-1042.	1.8	7
18	Positron Emission Tomographyâ€“Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group. Journal of Clinical Oncology, 2019, 37, 2835-2845.	0.8	151

#	Article	IF	Citations
19	Indirect determination of hematology reference intervals in adult patients on Beckman Coulter UniCell DxH 800 and Abbott CELL-DYN Sapphire devices. Clinical Chemistry and Laboratory Medicine, 2019, 57, 730-739.	1.4	18
20	Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV. Haematologica, 2019, 104, 955-962.	1.7	18
21	Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV. Leukemia, 2018, 32, 1222-1228.	3.3	22
22	Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO). Annals of Hematology, 2018, 97, 197-207.	0.8	162
23	Labelâ€Free Highâ€Throughput Leukemia Detection by Holographic Microscopy. Advanced Science, 2018, 5, 1800761.	5.6	50
24	Dual-targeting triplebody 33-16-123 (SPM-2) mediates effective redirected lysis of primary blasts from patients with a broad range of AML subtypes in combination with natural killer cells. OncoImmunology, 2018, 7, e1472195.	2.1	21
25	Measurements of immature platelets with haematology analysers are of limited value to separate immune thrombocytopenia from bone marrow failure. British Journal of Haematology, 2017, 177, 612-619.	1.2	28
26	Epidemiology of invasive aspergillosis and azole resistance in patients with acute leukaemia: the SEPIA Study. International Journal of Antimicrobial Agents, 2017, 49, 218-223.	1.1	71
27	Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. Lancet Haematology,the, 2017, 4, e510-e523.	2.2	258
28	Final Evaluation of Randomized CML-Study IV: 10-Year Survival and Evolution of Terminal Phase. Blood, 2017, 130, 897-897.	0.6	7
29	Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. Lancet Haematology,the, 2016, 3, e217-e227.	2.2	442
30	Real Life Experience with ATRA-Arsenic Trioxide Based Regimen in Acute Promyelocytic Leukemia - Updated Results of the Prospective German Intergroup Napoleon Registry. Blood, 2016, 128, 2815-2815.	0.6	1
31	Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial. Lancet, The, 2015, 385, 1418-1427.	6.3	154
32	Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML Study IV. Blood, 2015, 126, 42-49.	0.6	171
33	Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial. Lancet Oncology, The, 2015, 16, 1691-1699.	5.1	347
34	Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML. Annals of Hematology, 2015, 94, 2015-2024.	0.8	67
35	Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib. Haematologica, 2014, 99, 1441-1447.	1.7	97
36	Deep Molecular Response Is Reached by the Majority of Patients Treated With Imatinib, Predicts Survival, and Is Achieved More Quickly by Optimized High-Dose Imatinib: Results From the Randomized CML-Study IV. Journal of Clinical Oncology, 2014, 32, 415-423.	0.8	271

#	Article	IF	Citations
37	Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV. Annals of Hematology, 2014, 93, 71-80.	0.8	60
38	Older patients with chronic myeloid leukemia (â‰¥65Âyears) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV. Annals of Hematology, 2014, 93, 1167-1176.	0.8	21
39	Primary prophylaxis of invasive fungal infections in patients with haematologic malignancies. 2014 update of the recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology. Annals of Hematology, 2014, 93, 1449-1456.	0.8	88
40	Comparison of Automated Differential Blood Cell Counts From Abbott Sapphire, Siemens Advia 120, Beckman Coulter DxH 800, and Sysmex XE-2100 in Normal and Pathologic Samples. American Journal of Clinical Pathology, 2013, 139, 641-650.	0.4	103
41	Relapsed Hodgkin Lymphoma in Older Patients: A Comprehensive Analysis From the German Hodgkin Study Group. Journal of Clinical Oncology, 2013, 31, 4431-4437.	0.8	57
42	Rapid monitoring of immune reconstitution after allogeneic stem cell transplantation â€•a comparison of different assays for the detection of cytomegalovirusâ€šspecific T cells. European Journal of Haematology, 2013, 91, 534-545.	1.1	10
43	High-Dose Cytarabine Consolidation With or Without Additional Amsacrine and Mitoxantrone in Acute Myeloid Leukemia: Results of the Prospective Randomized AML2003 Trial. Journal of Clinical Oncology, 2013, 31, 2094-2102.	0.8	71
44	Measurement of immature platelets with Abbott CD-Sapphire and Sysmex XE-5000 in haematology and oncology patients. Clinical Chemistry and Laboratory Medicine, 2013, 51, 2125-2131.	1.4	47
45	Prognosis of patients with primary central nervous system lymphoma after high-dose chemotherapy followed by autologous stem cell transplantation. Haematologica, 2013, 98, 765-770.	1.7	82
46	Rationing Cancer Care: A Survey Among the Members of the German Society of Hematology and Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2013, 11, 658-665.	2.3	10
47	Therapy with antifungals decreases the diagnostic performance of PCR for diagnosing invasive aspergillosis in bronchoalveolar lavage samples of patients with haematological malignancies. Journal of Antimicrobial Chemotherapy, 2012, 67, 2260-2267.	1.3	85
48	Survey and analysis of the efficacy and prescription pattern of sorafenib in patients with acute myeloid leukemia. Leukemia and Lymphoma, 2012, 53, 1062-1067.	0.6	23
49	Diagnosing pulmonary aspergillosis in patients with hematological malignancies: a multicenter prospective evaluation of an <scp>A</scp>spergillus <scp>PCR</scp> assay and a galactomannan <scp>ELISA</scp> in bronchoalveolar lavage samples. European Journal of Haematology, 2012, 89, 120-127.	1.1	63
50	Treatment of B cell lymphoma with chemotherapy plus rituximab: a survival benefit can be demonstrated in the routine data of a regional cancer registry. Annals of Hematology, 2012, 91, 561-570.	0.8	11
51	Eight Cycles of Escalated-Dose BEACOPP Compared With Four Cycles of Escalated-Dose BEACOPP Followed by Four Cycles of Baseline-Dose BEACOPP With or Without Radiotherapy in Patients With Advanced-Stage Hodgkin's Lymphoma: Final Analysis of the HD12 Trial of the German Hodgkin Study Group. Journal of Clinical Oncology, 2011, 29, 4234-4242.	0.8	183
52	Prophylactic Application of Nebulized Liposomal Amphotericin B in Hematologic Patients with Neutropenia. Onkologie, 2011, 34, 254-258.	1.1	16
53	Tolerability-Adapted Imatinib 800 mg/d Versus 400 mg/d Versus 400 mg/d Plus Interferon-Î± in Newly Diagnosed Chronic Myeloid Leukemia. Journal of Clinical Oncology, 2011, 29, 1634-1642.	0.8	307
54	A phase II study of alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (Campath-FCD) in peripheral T-cell lymphomas. Leukemia and Lymphoma, 2010, 51, 447-455.	0.6	29

#	Article	IF	Citations
55	Active DNA demethylation in human postmitotic cells correlates with activating histone modifications, but not transcription levels. Genome Biology, 2010, 11, R63.	13.9	75
56	Pioglitazone and Rofecoxib Combined with Angiostatically Scheduled Capecitabine in Far-Advanced Hepatobiliary Carcinoma. , 2010, , 341-352.		0
57	Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology. Haematologica, 2009, 94, 113-122.	1.7	160
58	Optimaization of Imatinib Therapy by Combination. 5 Year Survival and Response Results of the Pilot Phase of the Randomized German CML STUDY IV.. Blood, 2009, 114, 862-862.	0.6	4
59	CCAAT Enhancer-binding Protein Î² Regulates Constitutive Gene Expression during Late Stages of Monocyte to Macrophage Differentiation. Journal of Biological Chemistry, 2007, 282, 21924-21933.	1.6	51
60	Liposomal Amphotericin B as Initial Therapy for Invasive Mold Infection: A Randomized Trial Comparing a High-Loading Dose Regimen with Standard Dosing (AmBiLoad Trial). Clinical Infectious Diseases, 2007, 44, 1289-1297.	2.9	663
61	Amphotericin B deoxycholate: no significant advantage of a 24 h over a 6 h infusion schedule. Journal of Antimicrobial Chemotherapy, 2007, 60, 180-182.	1.3	11
62	Imatinib in Chronic Myeloid Leukemia. New England Journal of Medicine, 2007, 356, 1780-1780.	13.9	5
63	Inhibitory effect of tumor cellâ€“derived lactic acid on human T cells. Blood, 2007, 109, 3812-3819.	0.6	1,361
64	Ifosfamide, epirubicin, and etoposide (IEV) mobilize peripheral blood stem cells more efficiently than cyclophosphamide/etoposide. Annals of Hematology, 2007, 86, 575-581.	0.8	5
65	Ex Vivo-activated Human Macrophages Kill Chronic Lymphocytic Leukemia Cells in the Presence of Rituximab: Mechanism of Antibody-dependent Cellular Cytotoxicity and Impact of Human Serum. Journal of Immunotherapy, 2006, 29, 388-397.	1.2	94
66	Monocyte-Derived Human Macrophages Mediate Anergy in Allogeneic T Cells and Induce Regulatory T Cells. Journal of Immunology, 2006, 177, 2691-2698.	0.4	54
67	Empirical antimicrobial monotherapy in patients after high-dose chemotherapy and autologous stem cell transplantation: a randomised, multicentre trial. British Journal of Haematology, 2005, 130, 265-270.	1.2	35
68	Treatment of Colon and Lung Cancer Patients with ex Vivo Heat Shock Protein 70-Peptide-Activated, Autologous Natural Killer Cells. Clinical Cancer Research, 2004, 10, 3699-3707.	3.2	224
69	Pioglitazone and rofecoxib combined with angiostatically scheduled trofosfamide in the treatment of far-advanced melanoma and soft tissue sarcoma. Cancer, 2004, 101, 2247-2256.	2.0	97
70	Elimination of activated but not resting primary human CD4 and CD8 T cells by Fas ligand (FasL/CD95L)-expressing Killer-dendritic cells. Immunobiology, 2004, 208, 463-475.	0.8	25
71	Hybrid Cell Vaccination in Metastatic Melanoma. Journal of Immunotherapy, 2004, 27, 147-155.	1.2	51
72	Transcriptional Regulation of CHI3L1, a Marker Gene for Late Stages of Macrophage Differentiation. Journal of Biological Chemistry, 2003, 278, 44058-44067.	1.6	212

#	Article	IF	Citations
73	The JAM-assay: optimized conditions to determine death-receptor-mediated apoptosis. Methods, 2003, 31, 127-134.	1.9	15
74	Species-specific Regulation of Toll-like Receptor 3 Genes in Men and Mice. Journal of Biological Chemistry, 2003, 278, 21502-21509.	1.6	174
75	Mature But Not Immature Fas Ligand (CD95L)-Transduced Human Monocyte-Derived Dendritic Cells Are Protected from Fas-Mediated Apoptosis and Can Be Used as Killer APC. Journal of Immunology, 2003, 170, 5406-5413.	0.4	36
76	The Treatment of Patients With Disseminated Malignant Melanoma by Vaccination With Autologous Cell Hybrids of Tumor Cells and Dendritic Cells. Journal of Immunotherapy, 2002, 25, 421-428.	1.2	74
77	Genomic Organization of the Human Gene HEP27: Alternative Promoter Usage in HepG2 Cells and Monocyte-Derived Dendritic Cells. Genomics, 2002, 79, 608-615.	1.3	20
78	Analysis of the Immune Response against Tetanus Toxoid: Enumeration of Specific T Helper Cells by the Elispot Assay. Immunobiology, 2002, 205, 282-289.	0.8	40
79	Structure of the human carboxypeptidase M gene. Identification of a proximal GC-rich promoter and a unique distal promoter that consists of repetitive elements. Gene, 2002, 284, 189-202.	1.0	18
80	Adoptive therapy with monocyte-derived macrophages in the setting of high-dose chemotherapy and peripheral blood stem cell transplantation. British Journal of Haematology, 2002, 116, 920-922.	1.2	3
81	PU.1 and Interferon Consensus Sequence-binding Protein Regulate the Myeloid Expression of the Human Toll-like Receptor 4 Gene. Journal of Biological Chemistry, 2000, 275, 9773-9781.	1.6	217
82	Carboxypeptidase M as a marker of macrophage maturation. Immunological Reviews, 1998, 161, 119-127.	2.8	29
83	Cytokine repertoire during maturation of monocytes to macrophages within spheroids of malignant and non-malignant urothelial cell lines. , 1998, 78, 648-653.		28
84	Comparative Analysis of Dendritic Cells Derived from Blood Monocytes or CD34+ Hematopoietic Progenitor Cells. Immunobiology, 1998, 198, 501-513.	0.8	44
85	Adoptive immunotherapy of cancer using monocyte-derived macrophages: rationale, current status, and perspectives. Journal of Leukocyte Biology, 1998, 64, 419-426.	1.5	127
86	Retinoic Acid Inhibits Monocyte to Macrophage Survival and Differentiation. Blood, 1998, 91, 4796-4802.	0.6	33
87	Retinoic Acid Inhibits Monocyte to Macrophage Survival and Differentiation. Blood, 1998, 91, 4796-4802.	0.6	1
88	Differential screening identifies genetic markers of monocyte to macrophage maturation. Journal of Leukocyte Biology, 1996, 60, 540-545.	1.5	187
89	Three-dimensional co-culture of human monocytes and macrophages with tumor cells: Analysis of macrophage differentiation and activation. , 1996, 66, 645-652.		40
90	Three-dimensional co-culture of human monocytes and macrophages with tumor cells: Analysis of macrophage differentiation and activation. , 1996, 66, 645.		5

#	Article	IF	Citations
91	Carboxypeptidase M Is Identical to the MAX.1 Antigen and Its Expression Is Associated with Monocyte to Macrophage Differentiation. Journal of Biological Chemistry, 1995, 270, 15644-15649.	1.6	71